Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Journal of Biological Chemistry|February 28, 2003
Mapping of a conformational epitope on plasminogen activator inhibitor-1 by random mutagenesis. Implications for serpin functionNatalia V Gorlatova, Hassan Elokdah, Kristi Fan, et al.
Journal of Medicinal Chemistry|June 25, 2004
Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterizationHassan Elokdah, Magid Abou-Gharbia, James K Hennan, et al.
Biochemical and Biophysical Research Communications|November 19, 2003
WAY-140312 reduces plasma PAI-1 while maintaining normal platelet aggregationDavid L Crandall, James K Hennan, Hassan Elokdah, et al.
The Journal of Biological Chemistry|February 6, 2007
Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitorNatalia V Gorlatova, Jacqueline M Cale, Hassan Elokdah, et al.
Blood|September 15, 2005
Pivotal role of PAI-1 in a murine model of hepatic vein thrombosisLayton H Smith, John D Dixon, John R Stringham, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 4, 2004
Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodelingAlec D Weisberg, Francisco Albornoz, Jane P Griffin, et al.
Molecular Pharmacology|July 12, 2007
Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of actionStephen J Gardell, Julie A Krueger, Thomas A Antrilli, et al.
Bioorganic & Medicinal Chemistry|July 13, 2007
Novel 1-(azacyclyl)-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines as 5-HT6 agonists and antagonistsHassan Elokdah, David Li, Geraldine McFarlane, et al.
Thrombosis and Haemostasis|April 9, 2008
Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosisSanjiv Baxi, David L Crandall, Thomas R Meier, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 30, 2005
Evaluation of PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic acid], a novel plasminogen activator inhibitor-1 inhibitor, in a canine model of coronary artery thrombosisJames K Hennan, Hassan Elokdah, Mauricio Leal, et al.
Pageof 2